Allworth Financial LP Purchases 33,897 Shares of Eli Lilly and Company $LLY

Allworth Financial LP raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 144.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,329 shares of the company’s stock after acquiring an additional 33,897 shares during the period. Allworth Financial LP’s holdings in Eli Lilly and Company were worth $44,690,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Cypress Capital LLC raised its stake in Eli Lilly and Company by 33.2% during the second quarter. Cypress Capital LLC now owns 678 shares of the company’s stock valued at $529,000 after purchasing an additional 169 shares in the last quarter. Tillman Hartley LLC increased its holdings in shares of Eli Lilly and Company by 15.4% in the 2nd quarter. Tillman Hartley LLC now owns 695 shares of the company’s stock worth $542,000 after buying an additional 93 shares during the last quarter. Americana Partners LLC raised its position in shares of Eli Lilly and Company by 3.1% during the 2nd quarter. Americana Partners LLC now owns 23,564 shares of the company’s stock valued at $18,369,000 after buying an additional 719 shares in the last quarter. BOK Financial Private Wealth Inc. lifted its holdings in shares of Eli Lilly and Company by 72.5% in the 2nd quarter. BOK Financial Private Wealth Inc. now owns 966 shares of the company’s stock valued at $753,000 after acquiring an additional 406 shares during the last quarter. Finally, Davis R M Inc. increased its stake in Eli Lilly and Company by 8.4% during the second quarter. Davis R M Inc. now owns 54,162 shares of the company’s stock worth $42,221,000 after acquiring an additional 4,195 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on LLY. BMO Capital Markets lifted their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Thursday. Guggenheim reaffirmed a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $960.88.

Eli Lilly and Company Trading Down 1.5%

Shares of LLY opened at $923.35 on Monday. The firm has a market capitalization of $872.92 billion, a price-to-earnings ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $955.46. The company has a 50-day moving average of $799.97 and a 200 day moving average of $775.01.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period last year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 4,314 shares of company stock worth $2,766,929 over the last quarter. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.